ClinicalTrials.gg
RecruitingNCT07140653Updated Oct 26, 2026

Arcuate Incisions With Light Adjustable Lens for Astigmatism Correction in Lens Surgery

A Phase 4 interventional study of Femto arcs and Light Adjustable Lens (LAL) in Astigmatism, sponsored by Center For Sight. Recruiting at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Center For Sight · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 26, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 161 studies in Astigmatism with a site in United States — 14 open to participants now, 21 under way, none of them phase 3. Astigmatism · United States.

Planned enrollment
61st of 127
60 · median 60
Started
2025
with 9 others
Phase 4
9 of 161
3 open now
Primary completion
2027-01
later than 10 of 20 live
Registered
147th of 161
by date

Among the 161 studies in Astigmatism with a site in United States, this one is the 61st largest by planned enrollment of the 127 interventional ones that give a count, is one of 10 that started in 2025, is one of 9 in phase 4, reaches primary completion later than 10 of the 20 other live ones, and was the 147th registered.

Astigmatism

418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.

Browse Astigmatism studies →

Open to participants now

14 of the 161 studies in Astigmatism with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Astigmatism with a site in United States, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and effectiveness of femtosecond laser arcuate corneal relaxing incisions (AK) combined with Light Adjustable Lens (LAL) implantation for correcting pre-existing corneal astigmatism in patients undergoing cataract or refractive lens exchange surgery. Postoperative assessments will focus on residual refractive astigmatism, visual outcomes, patient satisfaction, and the incidence of adverse events. Arcuate keratotomy and toric IOLs are well-established methods for astigmatism correction, and this study will compare their combined effectiveness using advanced femtosecond laser technology.

03

Conditions studied

  • Astigmatism

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be aged ≥ 21 years at the time of eligibility visit.
  2. Subject must have a vector difference of 0.50 D or less in magnitude of pre-operative anterior corneal astigmatism as measured by the Pentacam AXL and the Zeiss IOLMaster 700 (Carl Zeiss Meditec).
  3. Subject must be able and willing to comply with the study examination procedures.
  4. Astigmatic treatment must require paired arcs \<45mm in length.
  5. Subject must be willing to complete the approved form.
  6. Subject must have elected to undergo lens extraction and Light Adjustable Lens (LAL) implantation.
  7. Subject must be willing and able to return for scheduled pre-op and follow-up examinations.
  8. Subject must have central 7 mm of clear cornea without vascularization.

Exclusion criteria

Exclusion Criteria:

  1. Subject who has undergone previous corneal or intraocular surgery in the eye to be treated.
  2. Subject with a history, signs or symptoms of ocular disease or atypical findings that would be under standard of care for lens extraction surgery.
  3. Subject with neuro-ophthalmic disease.
  4. Diabetic or hypertensive subject with clinical evidence of retinal pathology that the investigator believes will significantly affect visual outcomes.
  5. Subject with macular degenerative pathology identified at the preoperative visit that the investigator believes will significantly affect visual outcomes.
  6. Subject with a history of -responsive rise in intraocular pressure (IOP), preoperative IOP >25 mmHg, or uncontrolled glaucoma in either eye.
  7. Subject with known lens/zonular instability.
  8. Subject who cannot achieve dilated pupillary diameter > 6 mm.
  9. Subject with abnormal corneal topography, including evidence of forme fruste keratoconus, keratoconus or pellucid marginal degeneration.
  10. Subject with posterior segment disease or degeneration.
  11. Subject with corneal disease or pathology that precludes an adequate view for imaging or transmission of laser wavelength of light.
  12. Subject with known sensitivity to planned perioperative standard of care medications.
  13. Subject participating in any other ophthalmic drug or device clinical trial during the time of this clinical assessment.
  14. Subject with known sensitivity to planned assessment concomitant medications.
  15. Subjects with severe dry eye syndrome (DES) or history of ocular inflammation that may impact visual outcomes.
  16. Subject with irregular astigmatism in the eye to be treated.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Femto arcs + LAL

    Other: Femto arcs · Device: Light Adjustable Lens (LAL)

Interventions

  • OtherFemto arcs

    Femtosecond laser-assisted arcuate corneal relaxing incisions (AK) will be performed to correct astigmatism.

  • DeviceLight Adjustable Lens (LAL)

    The LAL is intended to replace the natural lens at time of lens removal.

06

What researchers measure

Primary outcomes

  1. Number of LAL adjustments required to achieve the desired refraction

    Time frame: 8 weeks after last lock-in

Secondary outcomes

  1. Percentage of eyes with residual refractive astigmatism ≤ 0.50 D

    Time frame: 8 weeks after last lock-in

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Sep 2026 → Jan 2027 and completion Sep 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Aug 25, 2025
StartActual
Sep 2, 2025
Primary completionEst.
Jan 2, 2027was Sep 2026
CompletionEst.
Jan 2, 2027was Sep 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2, 2026→Jan 2, 2027
Oct 26, 2026
Study completion
Sep 2, 2026→Jan 2, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Sep 2, 2026→Jan 2, 2027
    Study completion Sep 2, 2026→Jan 2, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07140653
Lead sponsor
Center For Sight
Collaborators
LensAR Incorporated
Responsible party
Sponsor
First posted
Aug 25, 2025
Start date
Sep 2, 2025
Primary completion
Jan 2, 2027 (estimated)
Completion
Jan 2, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Helga P Sandoval
Contact
hps@cepmd.com
8438813937
Priya Mathews, MD
principal investigator · Center For Sight - Clinical Studies

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion